Career records & work history
Real Estate Brokers
Michael Gosselin
Specialties:
Buyer's Agent, Listing Agent
Michael W Gosselin, Age 46Duxbury, MA
Michael Gosselin Phones & Addresses
Duxbury, MA
Boston, MA
Jersey City, NJ
2 Maple Rd, North Hampton, NH 03862 (603) 964-9266
Vineyard Haven, MA
Keene, NH
Durham, NH
23 Willowdean Ave, West Roxbury, MA 02132 (617) 504-1348
Images
Mentions for Michael W Gosselin
Michael Gosselin resumes & CV records
Resumes
Michael Gosselin - Flagstaff, AZ
Work:
Ray Fusco Inc - New York, NY Jun 2013 to May 2014
Marketing Consultant Ray Fusco Inc - Poughkeepsie, NY Sep 2013 to Dec 2013
Advertising Sales Intern Laerdal Medical Corporation - Poughkeepsie, NY May 2013 to Aug 2013
Service Support Specialist Collegiate Entrepreneurs - Clinton, CT Feb 2011 to Dec 2011
Branch Manager
Marketing Consultant Ray Fusco Inc - Poughkeepsie, NY Sep 2013 to Dec 2013
Advertising Sales Intern Laerdal Medical Corporation - Poughkeepsie, NY May 2013 to Aug 2013
Service Support Specialist Collegiate Entrepreneurs - Clinton, CT Feb 2011 to Dec 2011
Branch Manager
Education:
Instituto Lorenzo de'Medici - Firenze, Toscana 2012
Advertising Marist College - Poughkeepsie, NY
Advertising Marist College - Poughkeepsie, NY
Skills:
Seasoned sales professional with marketing experience who is customer oriented, and is easily adaptable to various environments and situations. Also, has entrepreneurial drive and a self-starter mindset.
Michael Gosselin - Boston, MA
Work:
Daniel Webster College Oct 2013 to 2000
Writing Center Tutor Gourmet Caterers May 2012 to 2000
Server Boston University School of Management - Boston, MA May 2010 to Sep 2010
Lab Consultant Harborside Community Center - East Boston, MA 2007 to Jun 2008
Camp Counselor
Writing Center Tutor Gourmet Caterers May 2012 to 2000
Server Boston University School of Management - Boston, MA May 2010 to Sep 2010
Lab Consultant Harborside Community Center - East Boston, MA 2007 to Jun 2008
Camp Counselor
Education:
Daniel Webster College - Nashua, NH Mar 2013 to 2015
Bachelor of Science in Business Management
Bachelor of Science in Business Management
Michael Gosselin - Westhampton, MA
Work:
The Related Companies Mar 2012 to 2000
District Property Manager, Massachusetts Winn Residential - Boston, MA Jul 2010 to Nov 2011
Portfolio Asset Manager Community Management Corporation - Winston-Salem, NC Sep 2009 to Jul 2010
Regional Manager Intercoastal Group of Companies - Asheville, NC Apr 2008 to Sep 2009
Regional Director Preservation Management - Portland, ME Aug 2006 to Apr 2008
Regional Manager Harbor Management - Bangor, ME Mar 2005 to Aug 2006
Senior Property Manager Realty Resources Management - Bath, ME Jul 2003 to Mar 2005
Multi-Site Property Manager Carabetta Management - Springfield, MA Jul 2002 to Apr 2003
Property Manager Konover Investments - Northampton, MA Jan 2002 to Jul 2002
Property Manager Barkan Management - Boston, MA Dec 1999 to Jan 2002
Property Manager Arbor Management - Hartford, CT Jun 1999 to Dec 1999
Assistant Property Manager U.S. NAVY Jun 1987 to Jul 1991
Petty Officer 3rd Class
District Property Manager, Massachusetts Winn Residential - Boston, MA Jul 2010 to Nov 2011
Portfolio Asset Manager Community Management Corporation - Winston-Salem, NC Sep 2009 to Jul 2010
Regional Manager Intercoastal Group of Companies - Asheville, NC Apr 2008 to Sep 2009
Regional Director Preservation Management - Portland, ME Aug 2006 to Apr 2008
Regional Manager Harbor Management - Bangor, ME Mar 2005 to Aug 2006
Senior Property Manager Realty Resources Management - Bath, ME Jul 2003 to Mar 2005
Multi-Site Property Manager Carabetta Management - Springfield, MA Jul 2002 to Apr 2003
Property Manager Konover Investments - Northampton, MA Jan 2002 to Jul 2002
Property Manager Barkan Management - Boston, MA Dec 1999 to Jan 2002
Property Manager Arbor Management - Hartford, CT Jun 1999 to Dec 1999
Assistant Property Manager U.S. NAVY Jun 1987 to Jul 1991
Petty Officer 3rd Class
Education:
Grand Canyon University - Phoenix, AZ 2010 to 2012
MBA in Financing Northeastern University - Boston, MA 1998
Bachelors of Science St John's School of Business - West Springfield, MA
Certificate in Business Management and accounting procedures
MBA in Financing Northeastern University - Boston, MA 1998
Bachelors of Science St John's School of Business - West Springfield, MA
Certificate in Business Management and accounting procedures
Skills:
Financial Analysis & application of financial metrics, Yardi, OneSite, Boston Post. Certification in COS, Tax Credit, Site-based budgeting Specialist, Green management.
Publications & IP owners
Wikipedia
Mike Gosselin
Mike Goose Gosselin is a retired American soccer defender who earned one cap with the U.S. national team in 1992. He played professionally in the National...
Us Patents
Therapeutic Agents And Methods Of Use Thereof For Treating An Amyloidogenic Disease
US Patent:
2002013, Sep 19, 2002
Filed:
Nov 27, 2001
Appl. No.:
09/996357
Inventors:
Malcolm Gefter - Lincoln MA, US
David Israel - Concord MA, US
John Joyal - Melrose MA, US
Michael Gosselin - Melrose MA, US
David Israel - Concord MA, US
John Joyal - Melrose MA, US
Michael Gosselin - Melrose MA, US
Assignee:
Praecis Pharmaceuticals Inc. - Waltham MA
International Classification:
C07H021/04
A61K039/395
C12P021/02
C12N005/06
C07K016/40
A61K039/395
C12P021/02
C12N005/06
C07K016/40
US Classification:
536/023530, 530/391100, 424/178100, 435/069100, 435/326000, 435/320100
Abstract:
The present invention provides therapeutic agents suitable for treating an amyloidogenic disorder, as well as pharmaceutical compositions comprising the therapeutic agents and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an amyloidogenic disorder, e.g., Alzheimer's disease, in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
Serum Albumin Binding Molecules
US Patent:
2011030, Dec 15, 2011
Filed:
May 2, 2011
Appl. No.:
13/098851
Inventors:
Michael L. Gosselin - Boston MA, US
David Fabrizio - Swampscott MA, US
Joanna F. Swain - Concord MA, US
Tracy Mitchell - Billerica MA, US
Ray Camphausen - Wayland MA, US
Sharon T. Cload - Cambridge MA, US
Eric Furfine - Concord MA, US
Paul E. Morin - Pennington NJ, US
Ranjan Mukherjee - Churchville PA, US
Simeon I. Taylor - Skillman NJ, US
David Fabrizio - Swampscott MA, US
Joanna F. Swain - Concord MA, US
Tracy Mitchell - Billerica MA, US
Ray Camphausen - Wayland MA, US
Sharon T. Cload - Cambridge MA, US
Eric Furfine - Concord MA, US
Paul E. Morin - Pennington NJ, US
Ranjan Mukherjee - Churchville PA, US
Simeon I. Taylor - Skillman NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/20
C07K 19/00
A61K 38/17
A61P 3/10
A61P 3/04
A61K 38/18
A61K 38/28
A61K 38/22
A61K 38/26
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
A61P 3/00
A61P 3/06
A61P 9/00
C07K 14/47
C07K 19/00
A61K 38/17
A61P 3/10
A61P 3/04
A61K 38/18
A61K 38/28
A61K 38/22
A61K 38/26
C07H 21/00
C12N 15/63
C12N 5/10
C12N 1/21
A61P 3/00
A61P 3/06
A61P 9/00
C07K 14/47
US Classification:
424 852, 530324, 530350, 530399, 530351, 514 11, 514 69, 514 48, 514 91, 514 59, 514 88, 514 52, 514 72, 514 117, 514 97, 536 235, 4353201, 435325, 4352523
Abstract:
The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Therapeutic Methods Employing Sialylated Glycoforms Of Soluble Complement Receptor 1 (Scr 1)
US Patent:
5858969, Jan 12, 1999
Filed:
Jun 6, 1995
Appl. No.:
8/470867
Inventors:
Henry C. Marsh - Reading MA
Richard A.G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA
Richard A.G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA
Assignee:
T Cell Sciences, Inc. - Needham MA
International Classification:
A61K 3817
US Classification:
514 8
Abstract:
Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of. ltoreq. 5. 1, or have a sialic acid:mannose molar ratio of. gtoreq. 25.
Glycoform Fractions Of Recombinant Soluble Complement Receptor 1 (Scr1) Having Extended Half-Lives In Vivo
US Patent:
5456909, Oct 10, 1995
Filed:
Aug 7, 1992
Appl. No.:
8/927099
Inventors:
Henry C. Marsh - Reading MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne M. Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesley MA
Anne M. Freeman - Bucks, GB
Michael L. Gosselin - Chelsea MA
Assignee:
T Cell Sciences, Inc. - Needham MA
SmithKline Beecham p.l.c. - Brentwood
SmithKline Beecham p.l.c. - Brentwood
International Classification:
A61K 3836
A61K 3849
A61K 3849
US Classification:
424 9463
Abstract:
The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI. ltoreq. 5. 1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0. 25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.
Preparation And Use Of Sialylated Glycoforms Of Soluble Complement Receptor 1 (Cr1)
US Patent:
6057131, May 2, 2000
Filed:
Nov 5, 1998
Appl. No.:
9/186827
Inventors:
Henry C. Marsh - Reading MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesly MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Revere MA
Richard A. G. Smith - Relgate Surrey, GB
John Lifter - Wellesly MA
Anne Mary Freeman - Bucks, GB
Michael L. Gosselin - Revere MA
Assignee:
Avant Immunotherapeutics, Inc. - Needham MA
International Classification:
C12N 1512
C07K 1447
A61K 3817
C07K 1447
A61K 3817
US Classification:
435 691
Abstract:
Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of. ltoreq. 5. 1, or have a sialic acid: mannose molar ratio of. gtoreq. 25.
Serum Albumin-Binding Fibronectin Type Iii Domains
US Patent:
2022020, Jun 30, 2022
Filed:
Nov 16, 2021
Appl. No.:
17/527238
Inventors:
- Princeton NJ, US
Michael L. Gosselin - Boston MA, US
Dasa Lipovsek - Pepperell MA, US
Rex Parker - Titusville NJ, US
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Madison WI, US
David Fabrizio - South Hamilton MA, US
Michael L. Gosselin - Boston MA, US
Dasa Lipovsek - Pepperell MA, US
Rex Parker - Titusville NJ, US
Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Madison WI, US
David Fabrizio - South Hamilton MA, US
International Classification:
C07K 14/78
A61K 47/64
A61K 47/64
Abstract:
The present invention relates to polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Anti-Trem-1 Antibodies And Uses Thereof
US Patent:
2021040, Dec 30, 2021
Filed:
Sep 10, 2021
Appl. No.:
17/472302
Inventors:
- Princeton NJ, US
Michael L. GOSSELIN - Boston MA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Derek A. HOLMES - Lawrenceville NJ, US
Guodong CHEN - East Brunswick NJ, US
Priyanka Apurva MADIA - Franklin Park NJ, US
Richard Yu-Cheng HUANG - Bridgewater NJ, US
Stephen Michael CARL - Howell NJ, US
Michael L. GOSSELIN - Boston MA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Derek A. HOLMES - Lawrenceville NJ, US
Guodong CHEN - East Brunswick NJ, US
Priyanka Apurva MADIA - Franklin Park NJ, US
Richard Yu-Cheng HUANG - Bridgewater NJ, US
Stephen Michael CARL - Howell NJ, US
International Classification:
C07K 16/28
A61K 47/68
C12N 15/85
A61P 29/00
A61K 47/68
C12N 15/85
A61P 29/00
Abstract:
Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TRENT-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
Fast-Off Rate Serum Albumin Binding Fibronectin Type Iii Domains
US Patent:
2020028, Sep 10, 2020
Filed:
Jan 21, 2020
Appl. No.:
16/748085
Inventors:
- PRINCETON NJ, US
Tracy S. MITCHELL - Andover MA, US
Michael L. GOSSELIN - Boston MA, US
Dasa LIPOVSEK - Cambridge MA, US
Juhi JUNEJA - Lexington MA, US
Tracy S. MITCHELL - Andover MA, US
Michael L. GOSSELIN - Boston MA, US
Dasa LIPOVSEK - Cambridge MA, US
Juhi JUNEJA - Lexington MA, US
International Classification:
C07K 14/78
C07K 14/765
C12N 15/85
C07K 14/765
C12N 15/85
Abstract:
Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
Amazon
Smart Talk: Contemporary Interviewing And Interrogation With Just The Facts: Investigative Report Writing
Author:
Denise Kindschi Gosselin, Michael Biggs
Publisher:
Prentice Hall
Binding:
Paperback
Pages:
305
ISBN #:
0132948729
EAN Code:
9780132948722
This package contains the following components: -0131146963: Smart Talk: Contemporary Interviewing and Interrogation -013213280X: Just the Facts: Investigative Report Writing
NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.